In this edition of The Motley Fool's Market Checkup, health-care analysts David Williamson and Max Macaluso discuss the treatment of high cholesterol. From the impact of generic versions of Pfizer's Lipitor to the most exciting experimental drugs in late-stage clinical trials, cholesterol continues to be an area of focus for pharmaceutical companies and investors.
David Williamson owns shares of Pfizer and Amarin plc (ADR). Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.